Welcome to our dedicated page for Athira Pharma SEC filings (Ticker: ATHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Athira Pharma, Inc. (NASDAQ: ATHA) SEC filings page brings together the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Athira, which has announced a name change to LeonaBio, Inc. with a future ticker "LONA," uses filings such as Forms 8-K and 8-K/A to report material events related to its operations, capital structure and key licensing agreements.
Recent filings describe a 10-for-1 reverse stock split of common stock, implemented through a certificate of amendment in Delaware, and subsequent confirmation from The Nasdaq Stock Market that Athira regained compliance with the minimum bid price requirement. Other 8-K filings detail a private placement financing involving common stock, pre-funded warrants and accompanying common warrants, with gross proceeds expected to be approximately $90 million, and outline associated registration rights for investors.
Filings also cover Athira’s exclusive licensing arrangements for lasofoxifene with Sermonix Pharmaceuticals and Ligand Pharmaceuticals, including the assumption of responsibility for the global Phase 3 ELAINE-3 trial outside specified retained territories. These documents provide insight into how the company structures rights to develop, manufacture and commercialize oral forms of lasofoxifene and how it coordinates with partners.
On this page, users can review Athira’s current reports to understand how financing terms, warrant structures, reverse stock split mechanics and licensing obligations interact with its clinical programs in metastatic breast cancer and ALS. Stock Titan’s platform adds AI-powered summaries to help explain the key points of lengthy filings, highlight important dates and thresholds, and make it easier to interpret how each filing may relate to Athira/LeonaBio’s broader strategic and clinical plans.
A Schedule 13G/A reports that Steven Michael Oliveira and affiliated entities collectively disclose 161,218 shares of Athira Pharma common stock, representing 4.088% of the class. Nemean Asset Management, LLC is shown with 151,218 shares (3.834%) and South Ocean Capital LLC with 10,000 shares (0.253%), all filed from a common address in Jupiter, Florida. The filing states the holdings are shared voting and dispositive power and affirms the securities were not acquired to change or influence control of the issuer. Signatures show Oliveira as individual filer and authorized signer for the entities.
Athira Pharma, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received a notice on October 16, 2024 that its common stock had closed below $1.00 per share for 30 consecutive business days, triggering a deficiency under Nasdaq’s minimum bid requirement.
Nasdaq has now informed Athira that the closing bid price of its common stock was at least $1.00 per share for ten consecutive business days as of October 2, 2025. As a result, Athira is again in compliance with the minimum bid rule and Nasdaq has closed the deficiency matter.
Athira Pharma, Inc. is implementing a 10-for-1 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on September 17, 2025. This means every ten existing shares will be combined into one share, while the par value per share remains $0.0001.
The company is also reducing its authorized common stock from 900,000,000 to 90,000,000 shares and total authorized capital stock from 1,000,000,000 to 190,000,000 shares. Athira’s common stock is expected to begin trading on a post-split basis on The Nasdaq Capital Market on September 18, 2025 under the symbol ATHA.
Fractional shares resulting from the reverse split will be settled in cash, and proportional adjustments will be made to outstanding options, restricted stock units, and equity plan reserves. Stockholders holding shares in book-entry or through brokers will have their holdings automatically adjusted without needing to take action.
Athira Pharma, Inc. (NASDAQ: ATHA) has filed a Form 144, disclosing a proposed sale of 25,123 common shares through Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, on or about 01 Jul 2025. These shares equal roughly 0.06 % of the company’s 39,042,445 shares outstanding.
The shares were acquired on 30 Jun 2025 via a “Restricted Stock Lapse” tied to equity compensation. No other sales by the same insider have occurred in the past three months according to the filing. Aggregate market value is listed as 7,374 (units not specified). The sale will be executed on the NASDAQ exchange.
Because the transaction size is immaterial compared with ATHA’s float and no identity or role of the seller is provided, the filing is generally viewed as routine rather than a signal of strategic or operational change. Form 144 merely gives notice of intent; the sale may or may not ultimately occur. Investors may interpret the filing as normal portfolio or tax management following the vesting of stock-based compensation, rather than a negative assessment of Athira Pharma’s prospects.